Prevention of Unmitigated Chemotherapy-induced Emesis
Withdrawn before enrolling · Not applicable · Has a placebo group
Conditions studied: Chemotherapy-induced Nausea and Vomiting, Nausea Post Chemotherapy
In brief
Chemotherapy-induced nausea and vomiting (CINV) remains a major obstacle to patient care and continues to decrease quality of life. Despite the addition of medications and antiemetic regimens, doctors' ability to control CINV is still inadequate: even moderately-emetogenic chemotherapy regimens cause roughly 20% of patients to have vomiting and over 40% to experience significant nausea. In this study, the investigators test a transcranial vibrating system that has shown great promise at reducing nausea and vomiting. .
Key facts
- Study ID
- NCT03996863
- Run by
- Otolith Labs
- People needed
- 0
- Starts
- 2019-08-01
- Expected to finish
- 2019-08-01
- Last updated by the study team
- 2021-04-27
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subject currently receiving chemotherapy known to be emetogenic (i.e subject has already received one round of chemotherapy)
- MASCC Antiemesis Tool score of > 6 on the nausea severity scale and/or
- One or more episodes of vomiting anytime in the 4 days following receipt of chemotherapy and/or
- The need for three or more uses of rescue antiemetic medications within 4 days of chemotherapy during previous round.
You may not qualify if…
- Pregnant women
- Individuals unable to provide informed consent
- Any preexisting condition causing significant nausea or vomiting, or causing reaction to the bone conduction system (e.g. superior canal dehiscence)
- Prisoners
Where it is running
- I. Brodsky Associates Outpatient Hematology & Oncology Clinic — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.